License for destruction: Tumor-specific cytokine targeting

Research output: Contribution to journalLiterature reviewpeer-review

24 Citations (Scopus)
480 Downloads (Pure)


Stroma is an integral part of solid tumors and plays a key role in growth promotion and immune suppression. Most current therapies focus on destroying tumors and/or abnormal vasculature. However, evidence is emerging that anticancer efficacy improves with vessel normalization rather than destruction. Specific targeting of cytokines into tumors provides proof-of-concept that tumor stroma is dynamic and can be remodeled to increase drug access and alleviate immune suppression. Changing the inflammatory milieu ‘opens’ tumors for therapy and thus provides a license for destruction. This involves reprogramming of paracrine signaling networks between multiple stromal components to break the vicious cycle of angiogenesis and immune suppression. With active immunotherapy rapidly moving into the clinic, local cytokine delivery emerges as an attractive adjuvant.

Original languageEnglish
Pages (from-to)16-24
JournalTrends in Molecular Medicine
Issue number1
Early online date26 Oct 2013
Publication statusPublished - Jan 2014


Dive into the research topics of 'License for destruction: Tumor-specific cytokine targeting'. Together they form a unique fingerprint.

Cite this